Latest Manufacturing News

Alterity Therapeutics reports strengthened efficacy signals for ATH434 in Multiple System Atrophy and secures a robust cash position to fuel upcoming Phase 3 trials.

Australian Vanadium Limited advances its vertically integrated vanadium strategy with key regulatory approvals, manufacturing expansions, and a new $10 million loan facility, positioning itself for major energy storage projects.

NGX Limited progresses its Malingunde graphite project with key technical studies and downstream qualification, while advancing uranium exploration in Namibia. Market dynamics and regulatory shifts position NGX favorably in the clean energy minerals sector.

Argenica Therapeutics reports ARG-007 is safe in acute ischemic stroke patients and shows promising efficacy signals in a high-risk subgroup, paving the way for a focused Phase 2b trial.

West Cobar Metals reports significant progress across its WA and NSW projects, with promising assay results for rare earths and base metals, alongside strategic engagement in the US market and a recent $1.25 million capital raise.

Livium Ltd has completed its strategic pivot to focus on recycling clean energy waste, reporting solid Q1 FY26 results and securing a significant capital raise to fuel expansion into battery, solar panel, and rare-earth element recycling.

Race Oncology has filed pivotal patents on the active (E,E)-bisantrene isomer, potentially extending its drug exclusivity by two decades, while advancing its Phase 1 clinical trial and maintaining a strong cash position.

Percheron Therapeutics reports encouraging phase I clinical results for HMBD-002, confirming safety and early efficacy signals, while gearing up for a multi-arm phase II trial in 2026.

EQ Resources Limited reported a robust Q1 FY2026 with soaring tungsten prices, operational upgrades, and significant capital raises to fuel mine expansions.

Zoono Group Limited reports strong progress in its shelf-life extension technology with 50 active trials worldwide and anticipates its first significant sales this quarter, supported by fresh funding and expanding market interest.

Cann Group Limited has secured a short-term extension on its National Australia Bank debt facilities and is finalising a $15.3 million settlement deed to release all associated securities.

Resmed Inc. kicked off fiscal 2026 with robust 9% revenue growth and a notable 290 basis points gross margin expansion, signaling strong momentum in home healthcare innovation. The company also declared a $0.60 dividend and executed a $150 million share buyback, underscoring confidence in its strategic direction.